Advertisement

Supportive Care in Cancer

, Volume 25, Issue 11, pp 3515–3521 | Cite as

Management of infection during chemotherapy for acute leukemia in Japan: a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group

  • Shun-ichi Kimura
  • Hiroyuki FujitaEmail author
  • Hideaki Kato
  • Nobuhiro Hiramoto
  • Naoko Hosono
  • Tsutomu Takahashi
  • Kazuyuki Shigeno
  • Naoko Hatsumi
  • Hitoshi Minamiguchi
  • Junichi Miyatake
  • Hiroshi Handa
  • Nobu Akiyama
  • Yoshinobu Kanda
  • Minoru Yoshida
  • Hitoshi Kiyoi
  • Yasushi Miyazaki
  • Tomoki Naoe
  • Japan Adult Leukemia Study Group (JALSG)
Original Article

Abstract

Purpose

We performed a nationwide questionnaire-based survey to evaluate the current clinical practices of infectious complications during chemotherapy for acute leukemia in Japan.

Methods

We e-mailed a questionnaire to member institutions of the Japan Adult Leukemia Study Group in September, 2013. The questionnaire consisted of 50 multiple-choice questions covering therapeutic environment, antimicrobial prophylaxis, screening test during neutropenia, empirical therapy for febrile neutropenia, and the use of granulocyte-colony stimulating factor. The results were compared to those of previous surveys conducted in 2001 and 2007, and also to the recommendations described in the guidelines.

Results

Usable responses were received from 141 out of 222 (63.5%) institutions. Chemotherapy for acute myeloid leukemia was performed in protective environment in 90% of the institutions, which increased compared to previous survey (76%). Fluoroquinolones and fluconazole were the most commonly used antimicrobial agents for antibacterial and antifungal prophylaxis, followed by sulfamethoxazole-trimethoprim and itraconazole, respectively. In empirical therapy for febrile neutropenia, monotherapy with β-lactum antibiotics was the first-line therapy in most of the institutions. While empirical antifungal therapy was adopted for persistent fever in more than half of the institutions, preemptive/presumptive therapy was also used in approximately 40% of the institutions. Most of the clinicians were reluctant to use granulocyte-colony stimulating factor routinely in chemotherapy for acute myeloid leukemia.

Conclusions

This study clarified the current clinical practices of infectious complications during chemotherapy for acute leukemia and would provide important information for the development of a suitable guideline in Japan.

Keywords

Japan Adult Leukemia Study Group Acute leukemia Infectious complication Febrile neutropenia Antimicrobial prophylaxis Empirical therapy 

Notes

Acknowledgements

This work is supported in part by a grant from Japan Adult Leukemia Study Group.

Compliance with ethical standards

Conflict of interest

Shun-ichi Kimura received honoraria from Pfizer, Astellas, Sumitomo Dainippon Pharma, and Nippon Kayaku. Hiroyuki Fujita received honoraria from Novartis and payment for manuscripts from Chugai Pharmaceutical. Tsutomu Takahashi received grants from Chugai Pharmaceutical, Kyowa Hakko Kirin, and Astellas, and honoraria from Chugai Pharmaceutical, Kyowa Hakko Kirin, Taiho Pharmaceutical, and Celgene Corporation. Hiroshi Handa received payment for consultancy from Takeda Pharmaceutical, grants, and honoraria from Kyowa Hakko Kirin, Chugai Pharmaceutical, Takeda Pharmaceutical, Novartis, Bristol-Myers Squibb, Ono Pharmaceutical, and Astellas. Nobu Akiyama received grants from Shionogi, Sumitomo Dainippon Pharma, Taisho Toyama Pharmaceutical, and Astellas, and payment for manuscripts from Taiho Pharmaceutical. Yoshinobu Kanda received grants from Astellas, Chugai Pharmaceutical, Kyowa Hakko Kirin, Shionogi, Sumitomo Dainippon Pharma, Pfizer, and Taisho Toyama Pharmaceutical, and honoraria from Pfizer, MSD, Astellas, Sumitomo Dainippon Pharma, and Kyowa Hakko Kirin. Minoru Yoshida received honoraria from Astellas, Sumitomo Dainippon Pharma, and MSD. Hitoshi Kiyoi received research funding from Chugai Pharmaceutical, Bristol-Myers Squibb, Kyowa Hakko Kirin, Zenyaku Kogyo, FUJIFILM Corporation, Nippon Boehringer Ingelheim, Astellas, and Celgene Corporation, consulting fees from Astellas and Daiichi Sankyo, and honoraria from Bristol-Myers Squibb and Pfizer. Yasushi Miyazaki received grants from Chugai Pharmaceutical, Kyowa Hakko Kirin, Astellas, and Novartis, and honoraria from Chugai Pharmaceutical, Kyowa Hakko Kirin, Astellas, Sumitomo Dainippon Pharma, Celgene Corporation, and Novartis. Other authors: none to declare.

Supplementary material

520_2017_3775_MOESM1_ESM.doc (336 kb)
ESM 1 (DOC 335 kb)
520_2017_3775_MOESM2_ESM.docx (18 kb)
ESM 2 (DOCX 18 kb)

References

  1. 1.
    Japanese Society of Medical Oncology (2012) Practical guideline of febrile neutropenia (FN). Nankodo CO., Ltd., TokyoGoogle Scholar
  2. 2.
    Baer MR, Bernstein SH, Brunetto VL, Heinonen K, Mrozek K, Swann VL, Minderman H, Block AW, Pixley LA, Christiansen NP, Fay JW, Barcos M, Rustum Y, Herzig GP, Bloomfield CD (1996) Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemia Blood 87: 1484–1494Google Scholar
  3. 3.
    Cometta A, Kern WV, De Bock R, Paesmans M, Vandenbergh M, Crokaert F, Engelhard D, Marchetti O, Akan H, Skoutelis A, Korten V, Vandercam M, Gaya H, Padmos A, Klastersky J, Zinner S, Glauser MP, Calandra T, Viscoli C, International Antimicrobial Therapy Group of the European Organization for Research Treatment of C (2003) Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy Clin Infect Dis 37: 382–389CrossRefGoogle Scholar
  4. 4.
    Erjavec Z, de Vries-Hospers HG, Laseur M, Halie RM, Daenen S (2000) A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. J Antimicrob Chemother 45:843–849CrossRefGoogle Scholar
  5. 5.
    Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad, II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of A (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious Diseases Society of America Clin Infect Dis 52: e56–e93Google Scholar
  6. 6.
    Fujita H, Yoshida M, Miura K, Sano T, Kito K, Takahashi M, Shigeno K, Kanda Y, Akiyama N, Hatsumi N, Ohnishi K, Miyawaki S, Naoe T (2009) Management of infection in patients with acute leukemia during chemotherapy in Japan: questionnaire analysis by the Japan Adult Leukemia Study Group. Int J Hematol 90:191–198CrossRefGoogle Scholar
  7. 7.
    Gafter-Gvili A, Fraser A, Paul M, Leibovici L (2005) Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142:979–995CrossRefGoogle Scholar
  8. 8.
    Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G, Noens L, Szer J, Ganser A, O'Brien C, Matcham J, Barge A (1997) A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group Blood 90:4710–4718Google Scholar
  9. 9.
    Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751CrossRefGoogle Scholar
  10. 10.
    Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, Pizzo P, Rolston KV, Shenep JL, Young LS (1997) 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America Clin Infect Dis 25:551–573CrossRefGoogle Scholar
  11. 11.
    Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Meyers JD, Pizzo PA, Schimpff SC, Shenep JL, Wade JC, et al. (1990) From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever J Infect Dis 161: 381–396CrossRefGoogle Scholar
  12. 12.
    Kern WV, Klose K, Jellen-Ritter AS, Oethinger M, Bohnert J, Kern P, Reuter S, von Baum H, Marre R (2005) Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia Eur J Clin Microbiol Infect Dis 24: 111–118CrossRefGoogle Scholar
  13. 13.
    Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, Wilmer A, Verhaegen J, Boogaerts M, Van Eldere J (2005) Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study Clin Infect Dis 41: 1242–1250CrossRefGoogle Scholar
  14. 14.
    Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, Bretagne S (2012) ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients Bone Marrow Transplant 47: 846–854CrossRefGoogle Scholar
  15. 15.
    Masaoka T (2004) Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary Clin Infect Dis 39 Suppl 1: S49-52CrossRefGoogle Scholar
  16. 16.
    Morrissey CO, Chen SC, Sorrell TC, Milliken S, Bardy PG, Bradstock KF, Szer J, Halliday CL, Gilroy NM, Moore J, Schwarer AP, Guy S, Bajel A, Tramontana AR, Spelman T, Slavin MA (2013) Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial Lancet Infect Dis 13: 519–528CrossRefGoogle Scholar
  17. 17.
    Oshima K, Kanda Y, Asano-Mori Y, Nishimoto N, Arai S, Nagai S, Sato H, Watanabe T, Hosoya N, Izutsu K, Asai T, Hangaishi A, Motokura T, Chiba S, Kurokawa M (2007) Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipients. J Antimicrob Chemother 60:350–355CrossRefGoogle Scholar
  18. 18.
    Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE (2016) Sobel JD (2016) clinical practice guideline for the management of candidiasis. Update by the Infectious Diseases Society of America Clin Infect Dis 62:e1–50CrossRefGoogle Scholar
  19. 19.
    Tamura K (2005) Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group Int J Antimicrob Agents 26 Suppl 2: S123-127; discussion S133-140CrossRefGoogle Scholar
  20. 20.
    Tamura K, Akiyama N, Kanda Y, Saito M (2015) Efficacy and safety of tazobactam/piperacillin as an empirical treatment for the patients of adult and child with febrile neutropenia in Japan J Infect Chemother 21: 654–662CrossRefGoogle Scholar
  21. 21.
    Usuki K, Urabe A, Masaoka T, Ohno R, Mizoguchi H, Hamajima N, Miyazaki T, Niitsu Y, Yoshida Y, Miura A, Shibata A, Abe T, Miura Y, Ikeda Y, Nomura T, Nagao T, Saitou H, Shirakawa S, Ohkuma M, Matsuda T, Nakamura T, Horiuchi A, Kuramoto A, Kimura I, Irino S, Niho Y, Takatsuki K, Tomonaga M, Uchino H, Takaku F, Gran AMLSG (2002) Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study Br J Haematol 116: 103–112CrossRefGoogle Scholar
  22. 22.
    Yoshida M, Akiyama N, Fujita H, Miura K, Miyatake J, Handa H, Kito K, Takahashi M, Shigeno K, Kanda Y, Hatsumi N, Ohtake S, Sakamaki H, Ohnishi K, Miyawaki S, Ohno R, Naoe T (2011) Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group. Int J Hematol 93:66–73CrossRefGoogle Scholar
  23. 23.
    Yoshida M, Ohno R (2004) Antimicrobial prophylaxis in febrile neutropenia Clin Infect Dis 39 Suppl 1: S65-67CrossRefGoogle Scholar
  24. 24.
    Yoshida M, Ohno R (2004) Current antimicrobial usage for the management of infections in leukemic patients in Japan: results of a survey Clin Infect Dis 39 Suppl 1: S11-14CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Shun-ichi Kimura
    • 1
  • Hiroyuki Fujita
    • 2
    Email author
  • Hideaki Kato
    • 3
  • Nobuhiro Hiramoto
    • 4
  • Naoko Hosono
    • 5
  • Tsutomu Takahashi
    • 6
  • Kazuyuki Shigeno
    • 7
  • Naoko Hatsumi
    • 8
  • Hitoshi Minamiguchi
    • 9
  • Junichi Miyatake
    • 10
  • Hiroshi Handa
    • 11
  • Nobu Akiyama
    • 12
  • Yoshinobu Kanda
    • 1
    • 13
  • Minoru Yoshida
    • 14
  • Hitoshi Kiyoi
    • 15
  • Yasushi Miyazaki
    • 16
  • Tomoki Naoe
    • 17
  • Japan Adult Leukemia Study Group (JALSG)
  1. 1.Division of Hematology, Saitama Medical CenterJichi Medical UniversitySaitamaJapan
  2. 2.Department of HematologySaiseikai Yokohama Nanbu HospitalYokohamaJapan
  3. 3.Department of Hematology and Clinical ImmunologyYokohama City University Graduate School of MedicineYokohamaJapan
  4. 4.Department of HematologyKobe City Medical Center General HospitalKobeJapan
  5. 5.Department of Hematology and OncologyUniversity of FukuiFukuiJapan
  6. 6.Department of Oncology/HematologyShimane University HospitalIzumoJapan
  7. 7.Department of HematologyHamamatsu Medical CenterHamamatsuJapan
  8. 8.Leukemia Research CenterSaiseikai Maebashi HospitalMaebashiJapan
  9. 9.Department of Gastroenterology and HematologyShiga University of Medical ScienceOtsuJapan
  10. 10.Department of HematologySakai Hospital Kinki University Faculty of MedicineSakaiJapan
  11. 11.Department of Medicine and Clinical ScienceGunma University Graduate School of MedicineMaebashiJapan
  12. 12.Department of Hematology/OncologyTeikyo University School of MedicineTokyoJapan
  13. 13.Division of Hematology, Department of MedicineJichi Medical UniversityShimotsukeJapan
  14. 14.Fourth Department of Internal MedicineTeikyo University School of Medicine, Mizonokuchi hospitalKawasakiJapan
  15. 15.Department of Hematology and OncologyNagoya University Graduate School of MedicineNagoyaJapan
  16. 16.Department of Hematology and Molecular Medicine Unit, Atomic Bomb Disease InstituteNagasaki University Graduate School of Biomedical SciencesNagasakiJapan
  17. 17.National Hospital Organization Nagoya Medical CenterNagoyaJapan

Personalised recommendations